136 related articles for article (PubMed ID: 31112453)
1. Successful short desensitization for the eruption of hydroxychloroquine.
Hayami T; Tanaka T; Fujimoto N
Lupus; 2019 Jun; 28(7):918-919. PubMed ID: 31112453
[No Abstract] [Full Text] [Related]
2. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
Kishi C; Motegi SI; Yasuda M; Ishikawa O
J Dermatol; 2018 Aug; 45(8):1020-1022. PubMed ID: 30133802
[No Abstract] [Full Text] [Related]
3. A 6-step rapid desensitization protocol to hydroxychloroquine.
Sutton KM; Fernando SL
Ann Allergy Asthma Immunol; 2021 Mar; 126(3):292-293. PubMed ID: 33276119
[No Abstract] [Full Text] [Related]
4. Desensitization to hydroxychloroquine: alternative interpretations.
Sontheimer RD
J Rheumatol; 2007 Feb; 34(2):253-5; discussion 255. PubMed ID: 17304648
[No Abstract] [Full Text] [Related]
5. Desensitization to hydroxychloroquine--experience of 4 patients.
Mates M; Zevin S; Breuer GS; Navon P; Nesher G
J Rheumatol; 2006 Apr; 33(4):814-6. PubMed ID: 16463436
[TBL] [Abstract][Full Text] [Related]
6. Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work.
Matsuda T; Ly NTM; Kambe N; Nguyen CTH; Ueda-Hayakawa I; Son Y; Okamoto H
J Dermatol; 2018 Mar; 45(3):344-348. PubMed ID: 29239026
[TBL] [Abstract][Full Text] [Related]
7. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience.
Tal Y; Maoz Segal R; Langevitz P; Kivity S; Darnizki Z; Agmon-Levin N
Lupus; 2018 Apr; 27(5):703-707. PubMed ID: 28992797
[TBL] [Abstract][Full Text] [Related]
8. Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study.
Gonzalez CD; Hansen C; Clarke JT
J Am Acad Dermatol; 2019 Sep; 81(3):859-860. PubMed ID: 31085265
[No Abstract] [Full Text] [Related]
9. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Mittal L; Zhang L; Feng R; Werth VP
J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
[TBL] [Abstract][Full Text] [Related]
10. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
Pelle MT; Callen JP
Arch Dermatol; 2002 Sep; 138(9):1231-3; discussion 1233. PubMed ID: 12224986
[TBL] [Abstract][Full Text] [Related]
11. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
12. Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization.
Barailler H; Milpied B; Chauvel A; Claraz P; Taïeb A; Seneschal J; Darrigade AS
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):307-308. PubMed ID: 29800755
[No Abstract] [Full Text] [Related]
13. Drug-induced acute eosinophilic pneumonia due to hydroxychloroquine in a chilblain lupus patient.
Ishiguro Y; Muro Y; Murase C; Takeichi T; Kono M; Adachi R; Takahashi K; Akiyama M
J Dermatol; 2019 Oct; 46(10):e356-e357. PubMed ID: 31050015
[No Abstract] [Full Text] [Related]
14. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients.
Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M
J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729
[TBL] [Abstract][Full Text] [Related]
15. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
[TBL] [Abstract][Full Text] [Related]
16. Rapid desensitization of hydroxychloroquine.
Rowane M; Schend J; Patel J; Hostoffer R
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):97-98. PubMed ID: 31606403
[No Abstract] [Full Text] [Related]
17. [The everyday clinician. A wolf in sheep's clothing].
Théophile
Rev Med Brux; 2011; 32(5):490. PubMed ID: 22165530
[No Abstract] [Full Text] [Related]
18. Hydroxychloroquine-induced erythroderma.
Pai SB; Sudershan B; Kuruvilla M; Kamath A; Suresh PK
Indian J Pharmacol; 2017; 49(1):132-134. PubMed ID: 28458440
[TBL] [Abstract][Full Text] [Related]
19. Desensitization to hydroxychloroquine: 4 cases.
Caramaschi P; Barbazza R; Tinazzi I; Biasi D
J Rheumatol; 2011 Oct; 38(10):2267; author reply 2267. PubMed ID: 21965696
[No Abstract] [Full Text] [Related]
20. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine.
Ruzicka T; Sommerburg C; Goerz G; Kind P; Mensing H
Br J Dermatol; 1992 Nov; 127(5):513-8. PubMed ID: 1467292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
